Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...
Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...
Loma Linda University Medical Center, Loma Linda, California, United States
Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States
Forest Investigative Site 042, San Antonio, Texas, United States
Forest Investigative Site 063, Seattle, Washington, United States
Forest Investigative Site 017, Louisville, Kentucky, United States
Analgesic Solutions, Natick, Massachusetts, United States
Forest Investigative Site 033, Bullhead City, Arizona, United States
Forest Investigative Site 049, Whitehouse Station, New Jersey, United States
Forest Investigative Site 046, Greer, South Carolina, United States
California Medical Clinic for Headache, Santa Monica, California, United States
Women's Health Specialists, PLLC, Germantown, Tennessee, United States
Center for Musculoskeletal Pain Research, Gainesville, Florida, United States
Delray Research Associates, Delray Beach, Florida, United States
Columbia University Medical Center, New York, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.